Active substance: Sulbutiamine
Mode of action - regulating the metabolic processes in the central nervous system.
Enerion® The drug is a synthetic compound similar in structure to thiamine, in comparison with which the molecule has an outdoor thiazole ring, an additional disulfide bond, a lipophilic ester. With this modification sulbutiamine highly soluble in fats, rapidly absorbed from the gastrointestinal tract and readily crosses the blood-brain barrier; Unlike thiamine, can accumulate in the cells of the reticular formation, dentate gyrus and hippocampus, Purkinje cells and the glomeruli and granular layer of the cerebellar cortex. While taking Eneriona® improved coordination of movement and increases resistance to physical stress, increases the stability of the structures of the cerebral cortex to repetitive anoxia. The drug is effective in the symptomatic treatment of functional asthenia.
Sulbutiamine rapidly absorbed, Cmax of the drug in the blood plasma is achieved in 1-2 hours after administration. T1 / 2 -. About 5 hours The drug is excreted in the urine.
Symptomatic treatment of functional asthenia.
Hypersensitivity to any component of the drug.
Precautions: persons under 18 years (the drug is not recommended due to the lack of clinical data).
Pregnancy and breast-feeding
According to clinical studies, the drug does not affect the development of the fetus. However, due to lack of sufficient clinical data Enerion® is not recommended during pregnancy and while breastfeeding, because currently unknown, whether sulbutiamine able to penetrate into breast milk.
Allergic reactions (presence in the "Sunset" yellow colorant preparation), digestive disorders, neuropsychiatric reactions (tremor, headache, agitation, malaise).
Dosing and Administration
Inside. It is recommended for use only in adult patients.
Daily dose - Table 2-3. (400-600 mg) in 2 divided doses (breakfast and dinner). Duration of treatment should not exceed 4 weeks.
Symptoms: agitation with symptoms of euphoria and tremor of the limbs are transient and do not require special treatment.
The composition of excipients include lactose monohydrate formulation. As a consequence, this drug is not recommended for people with lactose deficiency, galactosemia or syndrome glucose / galactose malabsorption.
Effects on ability to drive and perform tasks requiring high speed of psychomotor reactions. Does not affect.
Film-coated tablets, 200 mg. According to Table 10. in a blister (PVC / aluminum). 2 blisters in a carton box. According to Table 15. in a blister (PVC / aluminum). At 2 or 4 blisters in a carton box.
"Servier Laboratories Industry" France. 905 Highway Saran, 45520 Zhidi, France.
Registration certificate issued by the company "Servier Laboratories", France.
Exporter ZAO "Pharmaceutical plant EGIS ', Hungary.
The temperature is not above 25 ° C.
Keep out of the reach of children.
The shelf life: 3 years.
Do not use beyond the expiration date printed on the package.